Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission

Core Insights - Bioxytran, Inc. has announced that its antiviral candidate PHM23 has been included in the University of Georgia's grant submission for the USDA's $100 million Highly Pathogenic Avian Influenza Poultry Innovation Grand Challenge, highlighting its potential against Bird Flu (H5N1) [1][4] - The selection of PHM23 underscores its effectiveness in neutralizing viral infections and its broad-spectrum antiviral activity, particularly against viruses similar to Bird Flu [2][7] - Bioxytran's CEO emphasized the significance of this recognition as validation of their galectin antagonist platform, which aims to safeguard animal health and the global food supply [3] Company Overview - Bioxytran, Inc. is focused on developing complex carbohydrate-based therapeutics to address unmet medical needs across three core platforms: virology, cancer metastasis, and oxygen transport [5] - The company is actively seeking partnerships with academic, industry, and government stakeholders to expedite the development and deployment of PHM23 in response to urgent global health needs [4] Technology and Mechanism - PHM23 operates by blocking viral spike proteins from attaching to host cells, a mechanism that minimizes the risk of viral mutations and offers hope for rapid containment of H5N1 outbreaks [3] - The technology aims to reduce the need for mass culling in poultry, potentially saving billions in annual losses to the poultry industry [3]